NO314142B1 - Nye strukturelle analoger av vitamin D - Google Patents

Nye strukturelle analoger av vitamin D Download PDF

Info

Publication number
NO314142B1
NO314142B1 NO19960099A NO960099A NO314142B1 NO 314142 B1 NO314142 B1 NO 314142B1 NO 19960099 A NO19960099 A NO 19960099A NO 960099 A NO960099 A NO 960099A NO 314142 B1 NO314142 B1 NO 314142B1
Authority
NO
Norway
Prior art keywords
mmol
solution
hexane
synthesis
compound
Prior art date
Application number
NO19960099A
Other languages
English (en)
Norwegian (no)
Other versions
NO960099L (no
NO960099D0 (no
Inventor
Roger Bouillon
Maurits Vandewalle
Pierre Jean De Clercq
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of NO960099D0 publication Critical patent/NO960099D0/no
Publication of NO960099L publication Critical patent/NO960099L/no
Publication of NO314142B1 publication Critical patent/NO314142B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/02—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen
    • C07C47/198—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C07C35/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
    • C07C35/27—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/02—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen
    • C07C47/19—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing hydroxy groups
    • C07C47/192—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing hydroxy groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/28—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/36—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/28—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/37—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/242—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/517—Saturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/743—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/26—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19960099A 1993-07-09 1996-01-09 Nye strukturelle analoger av vitamin D NO314142B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93202037 1993-07-09
PCT/EP1994/002294 WO1995001960A1 (fr) 1993-07-09 1994-07-07 Nouveaux analogues structuraux de la vitamine d

Publications (3)

Publication Number Publication Date
NO960099D0 NO960099D0 (no) 1996-01-09
NO960099L NO960099L (no) 1996-03-08
NO314142B1 true NO314142B1 (no) 2003-02-03

Family

ID=8213977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19960099A NO314142B1 (no) 1993-07-09 1996-01-09 Nye strukturelle analoger av vitamin D

Country Status (16)

Country Link
US (2) US6017907A (fr)
EP (2) EP0972762B1 (fr)
JP (2) JP4235256B2 (fr)
CN (1) CN1103755C (fr)
AT (2) ATE191712T1 (fr)
AU (1) AU699200B2 (fr)
CA (1) CA2166898C (fr)
DE (2) DE69423966T2 (fr)
DK (2) DK0972762T3 (fr)
ES (2) ES2147238T3 (fr)
GR (1) GR3033856T3 (fr)
NO (1) NO314142B1 (fr)
NZ (1) NZ271332A (fr)
PT (2) PT972762E (fr)
RU (1) RU2153491C2 (fr)
WO (1) WO1995001960A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2166898C (fr) * 1993-07-09 2004-09-07 Roger Bouillon Nouveaux analogues structurels de la vitamine d
JPH10509715A (ja) * 1994-11-21 1998-09-22 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １８，１９−ジノル−ビタミンｄ 化合物
US5661140A (en) * 1994-11-21 1997-08-26 Wisconsin Alumni Research Foundation 18-nor-vitamin D compounds
EP0771789B1 (fr) * 1995-10-30 2000-02-16 F. Hoffmann-La Roche Ag 1-alpha, 26-dihydroxy-D-homo-vitamine D3
WO1997016423A1 (fr) * 1995-10-31 1997-05-09 F.Hoffmann-La Roche Ag 24-homo-26,27-hexafluoro-cholecalciferols
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
DE19619036A1 (de) 1996-04-30 1997-11-13 Schering Ag Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
DE69804606T2 (de) * 1997-05-23 2002-11-07 Basilea Pharmaceutica Ag Binni Cyclohexandiolderivate
AUPO727097A0 (en) * 1997-06-10 1997-07-03 Unisearch Limited Method of treatment of hepatoma and pharmaceutical compositions for use therein
AU735676B2 (en) * 1997-06-10 2001-07-12 Mrc Holdings Pty Limited Method of treatment of liver tumours and pharmaceutical compositions for use therein
AU1022999A (en) * 1997-09-08 1999-03-29 F. Hoffmann-La Roche Ag 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
US5919986A (en) * 1997-10-17 1999-07-06 Hoffmann-La Roche Inc. D-homo vitamin D3 derivatives
AU2549099A (en) * 1998-02-24 1999-09-15 Chugai Seiyaku Kabushiki Kaisha 24-hydroxyvitamin d derivatives
US6184422B1 (en) * 1998-02-26 2001-02-06 Hoffman-La Roche Inc. Cyclohexanediol derivatives
WO1999049870A1 (fr) * 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamine d et ses analogues pour le traitement de tumeurs et d'autres troubles d'hyperproliferation
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity
US6479474B2 (en) 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
DE19935771A1 (de) * 1999-07-23 2001-02-01 Schering Ag Neue Vitamin D-Derivate mit cyclischen Substrukturen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
US6310262B1 (en) * 1999-10-18 2001-10-30 Basilea Pharmaceutica Ag Process for preparing retiferol derivatives
EP1106618A1 (fr) * 1999-12-08 2001-06-13 Laboratoire Theramex Précurseurs pour le cycle A de la vitamine D, procédé pour les préparer et intermédiaires de ce procédé
KR100732271B1 (ko) 1999-12-08 2007-06-25 라보라뚜와르 떼라멕스 비타민 디 전구체, 제조방법 및 중간체
GB0305332D0 (en) * 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
CA2528378A1 (fr) * 2003-06-11 2004-12-23 Novacea, Inc. Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d'autres agents therapeutiques
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
GB0422929D0 (en) * 2004-10-15 2004-11-17 Leuven K U Res & Dev Bioactive vitamin D analogues
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
GB0423091D0 (en) * 2004-10-19 2004-11-17 Leuven K U Res & Dev Bioactive vitamin d analogues
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
AU2006239883A1 (en) * 2005-04-22 2006-11-02 Novacea, Inc. Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof
WO2009094426A1 (fr) * 2008-01-22 2009-07-30 Wisconsin Alumni Reasearch Foundation Analogues 13,13-diméthyl-des-c,d de composés de 1-alpha, 25-dihydroxy-19-nor-vitamine d3 et formes posologiques de compositions topiques et procédés de traitement d'états pathologiques de la peau
US8109466B2 (en) * 2008-06-23 2012-02-07 Rohr, Inc. Thrust reverser cascade assembly and AFT cascade ring with flow deflector portion
SG2014006324A (en) * 2009-01-27 2014-03-28 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
EP2263677B1 (fr) * 2009-05-20 2011-04-13 Hybrigenics Nouvelles utilisations thérapeutiques de l'inécalcitol
CN106265695B (zh) 2009-08-14 2021-05-07 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
EP2360145B1 (fr) 2010-01-26 2012-03-21 Hybrigenics S.A. Nouveau procédé pour l'isomérisation de structures bicycliques fusionnées et préparation d'analogues de vitamine D comprenant celles-ci
WO2011144661A1 (fr) * 2010-05-20 2011-11-24 Roche Diagnostics Gmbh Réactif de libération pour composés de vitamine d
PL2407154T3 (pl) * 2010-07-15 2013-04-30 Hybrigenics Sa Formulacje 14-epi-analogów witaminy D
US20120015913A1 (en) 2010-07-15 2012-01-19 Delansorne Remi Formulations of 14-EPI-Analogues of Vitamin D
EP2407152A1 (fr) 2010-07-15 2012-01-18 Hybrigenics S.A. Formulations de 14-épi-analogues de la vitamine D
SG11201402196YA (en) 2011-11-18 2014-10-30 Hoffmann La Roche Release reagent for vitamin d compounds
EP2785687B1 (fr) 2011-11-30 2019-02-20 Sandoz AG Procédé de préparation de (3r)-2,4-di-groupe partant-3-méthylbut-1-ène
CN104024237B (zh) 2011-12-16 2016-02-24 阿方拉研究股份有限公司 用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体
JP6300030B2 (ja) 2011-12-29 2018-03-28 サンド アクツィエンゲゼルシャフト ２−（（２ｓ，３ｓ，４ｒ，５ｒ）−５−（（ｓ）−３−アミノ−２−ヒドロキシプロプ−１−イル）−４−メトキシ−３−（フェニルスルホニルメチル）テトラヒドロフラン−２−イル）アセトアルデヒド誘導体およびこれらを調製するためのプロセス
WO2013142999A1 (fr) 2012-03-30 2013-10-03 Alphora Research Inc. Procédé de synthèse pour la préparation d'analogues c1-céto macrocycliques de l'halichondrine b et intermédiaires utiles dans celui-ci
EP2970122B1 (fr) 2013-03-14 2019-05-08 Aquinox Pharmaceuticals (Canada) Inc. Modulateurs de ship1
WO2014143561A1 (fr) 2013-03-14 2014-09-18 Aquinox Pharmaceuticals Inc. Modulateurs de ship1 et méthodes associées
NZ714801A (en) 2013-05-29 2021-07-30 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d
GB2515128B (en) 2013-06-10 2015-05-27 Givaudan Sa Improvements in or relating to organic compounds
US9682914B2 (en) 2014-01-13 2017-06-20 P2 Science, Inc. Terpene-derived acids and esters and methods for preparing and using same
WO2015196019A1 (fr) 2014-06-20 2015-12-23 P2 Science, Inc. Ozonolyse par film dans un réacteur tubulaire ou multitubulaire
EP3177587A4 (fr) * 2014-08-06 2018-01-17 P2 Science, Inc. Parfums dérivés d'esters d'acides gras
GB201421855D0 (en) * 2014-12-09 2015-01-21 Givaudan Sa Improvements in or relating to organic compounds
CN107787315A (zh) 2015-06-26 2018-03-09 阿奎诺克斯药物（加拿大）公司 (1s,3s,4r)‑4‑((3as,4r,5s,7as)‑4‑(氨甲基)‑7a‑甲基‑1‑亚甲基八氢‑1h‑茚‑5‑基)‑3‑(羟甲基)‑4‑甲基环己醇的乙酸盐的结晶固体形式
US10053415B2 (en) 2016-01-20 2018-08-21 Aquinox Pharmaceuticals (Canada) Inc. Synthesis of a substituted indene derivative
WO2017223220A1 (fr) 2016-06-21 2017-12-28 P2 Science, Inc. Réacteurs à écoulement continu pour l'extinction continue de mélanges de peroxydes et procédés les comprenant
WO2018053289A1 (fr) 2016-09-16 2018-03-22 P2 Science, Inc. Utilisations de vanadium pour oxyder des aldéhydes et des ozonides
US11814350B2 (en) 2018-10-19 2023-11-14 P2 Science, Inc. Methods for disproportionation quenching of ozonides
CN110330522A (zh) * 2019-07-29 2019-10-15 南京海融医药科技股份有限公司 一种帕立骨化醇异构体杂质py5的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3590020C2 (de) * 1984-01-30 1995-03-09 Wisconsin Alumni Res Found In der Seitenkette ungesättigte 1-Hydroxyvitamin D-Verbindungen
CA1333616C (fr) * 1989-03-09 1994-12-20 Hector F. Deluca Composes de type 19-nor-vitamine d
NZ232734A (en) * 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
DE3913310A1 (de) * 1989-04-20 1990-10-25 Schering Ag Spirocyclopropane in der vitamin d-reihe
AU650751B2 (en) * 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
AU666563B2 (en) * 1992-08-07 1996-02-15 Wisconsin Alumni Research Foundation Preparation of 19-nor-vitamin D compounds
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag History of 52-carboxylic acid, processes for their preparation and pharmaceutical preparations containing them
CA2166898C (fr) * 1993-07-09 2004-09-07 Roger Bouillon Nouveaux analogues structurels de la vitamine d

Also Published As

Publication number Publication date
WO1995001960A1 (fr) 1995-01-19
DE69423966T2 (de) 2000-11-16
EP0707566B1 (fr) 2000-04-12
JP2006001944A (ja) 2006-01-05
NZ271332A (en) 2001-03-30
DK0972762T3 (da) 2004-02-09
AU7492794A (en) 1995-02-06
CN1130899A (zh) 1996-09-11
EP0972762A2 (fr) 2000-01-19
NO960099L (no) 1996-03-08
CA2166898A1 (fr) 1995-01-19
EP0707566A1 (fr) 1996-04-24
EP0972762B1 (fr) 2003-10-01
ATE251133T1 (de) 2003-10-15
DE69433220D1 (de) 2003-11-06
GR3033856T3 (en) 2000-10-31
ES2147238T3 (es) 2000-09-01
EP0972762A3 (fr) 2000-02-23
PT707566E (pt) 2000-09-29
US6017907A (en) 2000-01-25
AU699200B2 (en) 1998-11-26
US6548715B1 (en) 2003-04-15
CN1103755C (zh) 2003-03-26
ES2209327T3 (es) 2004-06-16
PT972762E (pt) 2004-02-27
JP4235256B2 (ja) 2009-03-11
DE69433220T2 (de) 2004-08-19
DK0707566T3 (da) 2000-09-04
JPH09500117A (ja) 1997-01-07
DE69423966D1 (de) 2000-05-18
RU2153491C2 (ru) 2000-07-27
ATE191712T1 (de) 2000-04-15
NO960099D0 (no) 1996-01-09
JP4312183B2 (ja) 2009-08-12
CA2166898C (fr) 2004-09-07

Similar Documents

Publication Publication Date Title
NO314142B1 (no) Nye strukturelle analoger av vitamin D
US5260290A (en) Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
JP4036490B2 (ja) ビタミンｄ化合物及びこれらの化合物の製造法
MXPA06005887A (es) Analogos de vitamina d para la prevencion y el tratamiento de la obesidad.
JPH02209888A (ja) ビタミンｄ↓２関連化合物
WO1985002189A1 (fr) Composes de la 1,25-dihydroxy-vitamine d2 et leurs procedes de preparation
EP0468042B1 (fr) DES COMPOSES DE VITAMINE D2 HOMOLOGUES ET LES DERIVES DE 1alpha-HYDROXYLES CORRESPONDANTS
CA2837549A1 (fr) Analogues de l'hyperforine, leurs methodes de synthese et leurs utilisations
AU2004230948A1 (en) 2-propylidene-19-nor-vitamin D compounds
RU2320644C2 (ru) Аналоги витамина d, композиции, содержащие указанные аналоги, и их применение
EP0157781B1 (fr) Composes de 1,23-dihydroxyvitamine d
JPH10509716A (ja) １８−ノルビタミンｄ化合物
Richardson Synthesis of Limonoid and Steroidal intermediates
Wang Part I. Noncalcemic, antiproliferative, transcriptionally active hybrid analogs of the hormone 1alpha, 25-dihydroxyvitamin D (3): Design, synthesis, and preliminary biological evaluation. Part II. New synthetic methodology: n+ 3 ring expansion cascade reactions
JP2818494B2 (ja) ビタミンＤ２ 化合物及び対応の１α−ヒドロキシル化誘導体の製造方法
Hutchinson The use of camphor in natural product synthesis
NO180537B (no) Fremgangsmåte for fremstilling av vitamin D2-forbindelser og de tilsvarende -hydroksylerte derivater
Dai Asymmetric total synthesis and preliminary biological activity evaluation of 1-substituted calcitriol analogs. Enantioselective Diels-Alder reactions of 3-carbonyl-2-pyrones and vinyl ethers promoted by chiral titanium species
DeLuca et al. 1, 25-dihydroxyvitamin D 2 compounds
TW200838544A (en) Synthesis of 1 α-fluoro-25-hydroxy-16-23E-diene-26, 27-bishomo-20-epi-cholecalciferol

Legal Events

Date Code Title Description
MK1K Patent expired